The estimated Net Worth of Kenneth C Cundy is at least $472 Thousand dollars as of 11 August 2021. Dr Cundy owns over 10,000 units of CohBar Inc stock worth over $8,600 and over the last 6 years he sold CWBR stock worth over $0. In addition, he makes $463,550 as Chief Scientific Officer at CohBar Inc.
Sign up
Dr Cundy CWBR stock SEC Form 4 insiders trading
Dr has made over 12 trades of the CohBar Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of CWBR stock worth $7,300 on 11 August 2021.
The largest trade he's ever made was exercising 17,981 units of CohBar Inc stock on 14 January 2020 worth over $13,126. On average, Dr trades about 7,857 units every 47 days since 2018. As of 11 August 2021 he still owns at least 20,000 units of CohBar Inc stock.
You can see the complete history of Dr Cundy stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Kenneth C. Cundy biography
Dr. Kenneth C. Cundy is the Chief Scientific Officer at CohBar Inc.
What is the salary of Dr Cundy?
As the Chief Scientific Officer of CohBar Inc, the total compensation of Dr Cundy at CohBar Inc is $463,550. There are 2 executives at CohBar Inc getting paid more, with Steven Engle having the highest compensation of $2,410,850.
How old is Dr Cundy?
Dr Cundy is 62, he's been the Chief Scientific Officer of CohBar Inc since . There are 7 older and 5 younger executives at CohBar Inc. The oldest executive at CohBar Inc is Albion Fitzgerald, 71, who is the Independent Chairman of the Board.
What's Dr Cundy's mailing address?
Kenneth's mailing address filed with the SEC is C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK, CA, 94025.
Insiders trading at CohBar Inc
Over the last 7 years, insiders at CohBar Inc have traded over $0 worth of CohBar Inc stock and bought 586,523 units worth $136,480 . The most active insiders traders include Misha Petkevich, Kenneth C Cundy, and Jon Leland Stern. On average, CohBar Inc executives and independent directors trade stock every 22 days with the average trade being worth of $9,727. The most recent stock trade was executed by David Greenwood on 1 November 2021, trading 20,000 units of CWBR stock currently worth $8,600.
What does CohBar Inc do?
cohbar (otcqx: cwbr and tsxv: cob.u) is the leader in the research and development of mitochondria-based therapeutics (mbts), an emerging class of drugs for the treatment of diseases associated with aging. mbts originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. this groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. mbts offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.
What does CohBar Inc's logo look like?
Complete history of Dr Cundy stock trades at CohBar Inc
CohBar Inc executives and stock owners
CohBar Inc executives and other stock owners filed with the SEC include:
-
Steven Engle,
Chief Executive Officer, Director -
Phyllis Gardner,
Independent Director -
Dr. Kenneth C. Cundy,
Chief Scientific Officer -
Jeffrey F. Biunno CPA, M.B.A., CPA, MBA,
CFO, Treasurer & Sec. -
Kenneth Cundy,
Chief Scientific Officer -
David Greenwood,
Independent Director -
Jeffrey Biunno,
Chief Financial Officer, Treasurer, Secretary -
Jon Stern,
Director -
Misha Petkevich,
Independent Director -
Albion Fitzgerald,
Independent Chairman of the Board -
Pinchas Cohen,
Independent Director -
Nir Barzilai,
Independent Director -
Jordyn Tarazi,
Director of Investor Relations -
Dr. Rohit Loomba,
Scientific Consultant -
Dr. Changhan David Lee Ph.D.,
Consultant of Mitochondrial Biology -
Dr. David Andrew Sinclair A.O., Ph.D.,
Co-Founder, Advisor & Consultant -
Dr. Joseph J. Sarret,
CEO & Director -
Simon Allen,
Chief Executive Officer -
Marc E. Goldberg,
-
Philippe Calais,
Director -
Joseph J. Sarret,
Chief Executive Officer -
John Amatruda,
Director -
Carol Nast,
Director -
Joanne Yun,
Director -
Stephanie Tozzo,
Director